Latest Epidermal growth factor receptor Stories
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients.
MISSISSAUGA, ON, Aug. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc.
RIDGEFIELD, Conn., Aug.
Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.
The cause of lung cancer in never-smokers is poorly understood, but a study led by investigators at the Ohio State University Comprehensive Cancer Center and at the National Cancer Institute has identified a molecule believed to play an early and important role in its development.
Epidermal Growth Factor Receptor Mutation Test May Be Key To Identifying Patient Response to Drug Therapies ALISO VIEJO, Calif., June 16 /PRNewswire-FirstCall/ -- Clarient, Inc.
EGFR Pathway Test analyzes in sequential reflex fashion more mutations potentially inhibiting anti-EGFR therapy response in metastatic colorectal cancer patients MADISON, N.J., June 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company, today launched the EGFR Pathway test (KRAS with reflex to NRAS, BRAF), the first laboratory-developed test from a national commercial reference laboratory for comprehensively identifying, in a...
A class of drugs already approved as cancer treatments might also help to beat alcohol addiction.
- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2) -The First Presentation of Data on BIBF 1120 in Ovarian Cancer- RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Boehringer Ingelheim will present new data on the company's two lead oncology compounds, BIBW 2992 and BIBF 1120 at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company...
Test will help oncologists guide treatment of patients with non-small cell lung cancer BROOMFIELD, Colo., May 5 /PRNewswire/ -- Biodesix, Inc. today announces U.S.
- A hairdresser.